Category Archives: News

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint has today announced the successful pricing of the reset of Bridgepoint CLO V.

The transaction extends the investment period to 2030 and lowers the cost of capital of the original 2023 deal.

Bridgepoint’s third CLO transaction of 2025, the reset saw strong demand throughout the full capital stack, evidencing the market’s continued appetite for Bridgepoint’s disciplined approach to investment and credit selection.

Commenting on the transaction, John Murphy, Partner and Bridgepoint’s Head of Syndicated Debt, said:

“We’re pleased to have seen such strong continued interest from our broader investor base with the reset of Bridgepoint CLO V. By combining a long-term reinvestment horizon with a flexible, high-conviction approach to portfolio management, we’ve shown our platform can adapt to changing markets and unlock consistent value. This robust investor demand speaks to the trust placed in our differentiated approach.”

With more than €14 billion of assets under management in corporate credit across the risk/reward spectrum, Bridgepoint Credit is one of Europe’s most experienced credit managers. It focuses on three complementary investment strategies: Direct Lending, Credit Opportunities and Syndicated Debt.

Bridgepoint Group is one of the world’s leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit.

With over $86 billion of assets under management and a strong local presence in Europe, North America and Asia, we combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles.

Bridgepoint Advisers Limited, a subsidiary of Bridgepoint Group plc, is authorised and regulated by the Financial Conduct Authority.

Categories: News

Tags:

Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

Abingworth

– Spin-out of Scorpion Therapeutics, led by former Scorpion Therapeutics management team –

– Advancing multiple programs across cancer and other serious diseases; plans to advance first new product candidate into the clinic in 2026 –

– Series A financing co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from other leading healthcare funds –

BOSTON, Mass. – June 10, 2025 – Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors.

Antares is a spin-out of Scorpion Therapeutics, Inc. (“Scorpion”), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company (“Lilly”) in March 2025 for up to $2.5 billion in total consideration. Scorpion was founded in 2020 and, in the subsequent five years, raised a total of $420 million in financing, executed partnerships with multiple pharmaceutical companies, and generated six development candidates, three of which are in clinical testing. Antares is led by Scorpion’s former executive leadership team and is advancing a pipeline of small molecule assets developed at Scorpion, including programs in precision oncology and other therapeutic areas, as well as programs initiated through Scorpion’s 2022 transcription factor collaboration with AstraZeneca.

“We took our name from Antares, the brightest star in the Scorpius constellation, and known as ‘the heart of the Scorpion.’ We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares and former Chief Executive Officer of Scorpion. “We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.”

“At Omega, we focus on identifying approaches and working with exceptional teams to deliver impactful products to patients,” said Otello Stampacchia, Ph.D., Founder and Managing Director at Omega Funds. “Antares meets each of these criteria. As one of the founding investors in Scorpion, we have had the opportunity to follow the company’s evolution very closely and have been consistently impressed by the breadth of the team’s capabilities, as well as their scientific rigor and rapid execution. I look forward to seeing the company’s vision advance by delivering differentiated, first-in-class products to treat some of the most important unmet medical needs.”

Additionally, Antares announced that Pierre Fabre Laboratories, with whom Scorpion previously partnered to advance two clinical-stage, highly selective next-generation mutant EGFR inhibitors for the treatment of non-small cell lung cancer, has acquired global rights to both programs. Under the terms of the agreement, Pierre Fabre Laboratories will lead the continued clinical development and global commercialization of both programs, and Antares will be eligible to receive regulatory and commercial milestones and tiered royalties.

Antares’ leadership team

Antares is led by the former Scorpion executive team, including leaders with accomplished track records in the biotechnology industry:

  • Adam Friedman, M.D., Ph.D., Chief Executive Officer
  • Natasja Brooijmans, Ph.D., Executive Vice President, Discovery Predictive Sciences
  • Mark Chao, M.D., Ph.D., Chief Medical Officer
  • Andrew Fedder, General Counsel
  • Angel Guzman-Perez, Ph.D., Executive Vice President, Head of Chemistry
  • Erica Jackson, Ph.D., Chief Scientific Officer
  • Darrin Stuart, Ph.D., Chief Development Officer
  • Amanda Valentino, Chief People Officer

The company’s Board of Directors are industry veterans with company-building expertise, as well as experience pioneering breakthrough medicines:

  • Jeff Albers, J.D., M.B.A., Board Chair at Antares Therapeutics and Venture Partner at Atlas Venture
  • Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners
  • Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School
  • Jean-François Formela, M.D., Partner at Atlas Venture
  • Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares Therapeutics
  • Sir Menelas Pangalos, Ph.D., formerly Executive Vice President of Biopharmaceuticals R&D at AstraZeneca

“After years of investment into its proprietary drug discovery capabilities, the team at Antares has made notable progress to unlock the therapeutic potential of targets long seen as important – but undruggable – like the large class of transcription factors,” said Sir Menelas Pangalos, Ph.D., independent member of the Antares Board. “I look forward to partnering with the Antares team as they address some of the most complex challenges in science.”

“Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,” said Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center. “This team has demonstrated an ability to break through longstanding limits in medicinal chemistry to advance a pipeline of first-in-class assets, aiming to change the treatment landscape for patients.”

About Antares Therapeutics

Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares’ most advanced program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development. To learn more, visit www.antaresrx.com and follow us on LinkedIn.

Media Contact:
Emily Anderson
emily.anderson@antaresrx.com

Investor Contact:
Danielle Dudgeon
Precision AQ
danielle.dudgeon@precisionaq.com

Categories: News

Tags:

WEAVE LIVING and KKR Build on Strategic Partnership with Acquisition of Portfolio of Residential Properties in Prime Central Tokyo

KKR

Over 240 new units in upscale Tokyo locations set to open from Autumn 2025

TOKYO–(BUSINESS WIRE)– WEAVE LIVING, Asia-Pacific’s pre-eminent living sector specialist, and KKR, a leading global investment firm, today announced the signing of definitive agreements to acquire six properties in prime Tokyo locations. The move builds on the continued momentum of the Weave Living Japan Residential Venture I (“WLJRV I”) strategic partnership between WEAVE LIVING and KKR. With the latest acquisitions, the strategic partnership has grown its portfolio to 17 properties within the first six months of its establishment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609398797/en/

Three of these new acquisitions are located in Tokyo’s upscale Minato ward neighbourhoods of Roppongi, Minami Azabu and Shirokane. WEAVE LIVING will also introduce its premium WEAVE RESIDENCES brand as part of its Roppongi and Minami Azabu offerings, featuring luxurious, metropolitan living in spacious, fully furnished family-friendly homes, complete with modern decor, and thoughtful design finishes. These homes will help meet growing demand by discerning executives seeking an elevated living experience in the supply-constrained Minato area.

The remaining locations will expand the WEAVE PLACE brand, offering beautifully designed private apartments with various furnished options catering to the respective needs of a diverse tenant base including local professionals, expatriates and corporates. Under these plans, more than 240 fully-furnished luxury rental properties are expected to be ready starting from fall 2025.

“As part of our steady growth in the Japan market and across Asia-Pacific, we are thrilled to expand our collaboration with KKR and our Japan-based offering to six new locations that are extremely desirable even by Tokyo standards,” said Sachin Doshi, Founder and Group CEO of WEAVE LIVING. “Also factoring in the planned Japan debut of our WEAVE RESIDENCES brand, this is a further demonstration of our commitment to offering an ever-wider selection of living options to renters at various life stages, with an emphasis on the distinctive attractiveness of each of the fantastic locations that make up our expanded portfolio in Tokyo.”

Kensuke Kudo, Managing Director, Real Estate, KKR, said, “We are proud of the strong momentum that our strategic partnership with WEAVE LIVING has achieved in a short span of time. This expansion underscores our conviction in the long-term fundamentals of Japan’s residential sector and ability to deliver high-quality, differentiated offerings to meet the evolving residential needs of corporates and executives in Japan. We look forward to continued collaboration with Sachin to scale this promising platform.”

KKR is making its investment from its Asia real estate strategy. The transaction adds to KKR’s continued activity and momentum in Japan’s real estate sector across different real estate investment strategies, including KJR Management, a leading Japanese real estate manager that oversees two J-REITs; hospitality and office assets across Japan; and a portfolio of multifamily properties in Tokyo.

A full overview of WEAVE LIVING’s existing Tokyo locations can be found on the recently revamped WEAVE LIVING website, along with details on a unique rental offering that includes flexible lease periods; transparent payment plans inclusive of all Wi-Fi and utilities; a fully digital-first leasing experience; tenant support via the proprietary WEAVE LIVING mobile app; and a welcome respite from prohibitive up-front charges typical in the Japanese multi-family rental market.

Leasing enquiries
Tel: (+81) 03-6262-5628
Email: live.jp@weave-living.com

Existing locations: Weave Place – Shinkamata, Weave Place – Kanda East, Weave Place – Asakusa South, Weave Place – Asakusa Kaminarimon, Weave Place – Ueno South, Weave Place – Waseda Park, Weave Place – Higashi-Koenji, Weave Place – Monzennakacho, Weave Place – Morishita, Weave Place – Ryogoku, Weave Place – Kunitachi

For full details of property lineup and available units, and to request viewings, please visit https://www.weave-living.com/en/jp/

About WEAVE LIVING
Weave Living is a leading provider of urban rental accommodation in key gateway cities throughout Asia Pacific. Since its founding in 2017 by Sachin Doshi, Weave has reimagined renting a home in big cities so more people can live their best life, wherever they are on their adventure. Weave currently offers four unique living options that cater to a diverse range of modern lifestyles: luxurious Weave Residences; fully serviced Weave Suites; self-contained Weave Place; and social co-living Weave Studios. Each class-leading home combines modern aesthetics, superior finishes, and a fully tech-enabled experience together with superior comfort and flexibility in the best urban locations. At present, Weave owns and manages residential properties in Hong Kong, Singapore, Japan, and South Korea, with more on the way.

Weave Living
Website: https://www.weave-living.com/en/jp
Instagram: @liveatweave
Facebook: @liveatweave

About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media Enquiries
This press release is disseminated by Kyodo PR on behalf of Weave Living. For more information or for interview opportunities, please contact:

David McMahon (English)
Email: davidhoward.mcmahon@kyodo-pr.co.jp
Tel: (+81) 080-8914-9376

Aya Asoshina (Japanese)
Email: a-asoshina@kyodo-pr.co.jp
Tel: (+81) 070-4303-7299

For KKR:
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

Source: KKR

 

Download PDF

Categories: News

Tags:

HarbourView Closes on $500 Million in Additional Debt Financing from KKR

KKR

NEWARK, N.J., June 9, 2025 /PRNewswire/ — HarbourView Equity Partners (HarbourView), an alternative asset management company focused on investment opportunities in the entertainment, media, and sports space, with approximately *$2.67B in regulatory assets under management, has closed an additional $500 million in debt financing through a new private securitization backed by its diversified, scaled music portfolio. Insurance vehicles managed by KKR, a leading global investment firm, participated in the transaction.

This latest financing expands on the nearly $500 million in debt financing HarbourView secured in 2024 from KKR-managed insurance vehicles and accounts and other investors.

“We are thrilled to have KKR’s continued support as we further scale the firm,” said HarbourView Founder and CEO Sherrese Clarke. “This additional capital from KKR will help us accelerate our strategy to align with where the media, sports and entertainment markets are headed. We see a tremendous opportunity to continue investing in evergreen intellectual property, which we believe is historically uncorrelated to broader market volatility and forms a powerful diversification tool.”

“We are pleased to further support HarbourView and to invest in this well-diversified, scaled and high-quality portfolio through our High-Grade Asset-Based Finance strategy. Music IP is one of many areas of opportunity that we see for this strategy and an example of its breadth,” said Avi Korn and Chris Mellia, Global Co-Heads of Asset-Based Finance at KKR.

KKR’s Asset-Based Finance (ABF) strategy focuses on privately originated and negotiated credit investments that are backed by large and diversified pools of financial and hard assets, offering diversification to traditional corporate credit and attractive risk-adjusted returns. KKR’s ABF platform began investing in 2016 and now has approximately $74 billion in ABF assets under management globally across its High-Grade ABF and Opportunistic ABF strategies.

Established in 2021, HarbourView Equity Partners has solidified its position in the industry, building a distinctly diverse portfolio featuring thousands of titles spanning numerous genres, eras, and artists. With data analytics and value creation at its core, the firm seeks to deliver differentiated returns in partnership with the creative ecosystem. The firm has acquired over 70 music catalogs encompassing over 35,000 songs across both master recordings and publishing income streams. The company most recently made a deal to finance a slate of Hip Hop biopics in partnership with Will Smith’s Westbrook Studios, Flavor Unit and Jesse Collins Entertainment, starting with a Queen Latifah biopic. This followed an investment in Usher’s 2024 concert film “Rendezvous in Paris.”

The financing, solely structured by Barclays, further emphasizes HarbourView’s commitment to targeting the best execution for its growing LP base and comes on the heels of numerous major deals.

“Barclays is proud to once again support HarbourView. This deal underscores the strong demand from investors for uncorrelated assets and highlights our track record of supporting music and media companies in accessing efficient, scalable capital,” said Salina Sabri, Managing Director, Securitized Products Origination at Barclays. “We are grateful to play a small role in HarbourView’s continued growth”.

Barclays served as sole structuring advisor in this transaction. Barclays and KKR Capital Markets acted as placement agents, and Fifth Third Bank, National Association as passive placement agent.

About HarbourView Equity Partners

HarbourView Equity Partners is an investment firm focused on opportunities to support premium content across the entertainment, sports, and media markets. The firm seeks businesses or assets powered by IP and investment opportunities that aim to build enduring asset value and returns. HarbourView has been extremely active since launching in 2021, amassing roughly $2.67 billion* in regulatory assets under management including over 70+ music catalogs to date and investments in various portfolio companies with management teams in its core industries. The firm’s distinctly diverse music portfolio features thousands of titles spanning numerous genres, eras, and artists, amounting to a diversified catalog of ~35,000+ songs across both master recordings and publishing income streams. The company is headquartered in Newark, NJ.

Home Page ● LinkedIn ● Instagram ● Facebook

* Unaudited as of 12/31/2024

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Barclays

Our vision is to be the UK-centred leader in global finance. We are a diversified bank with comprehensive UK consumer, corporate and wealth and private banking franchises, a leading global investment bank and a strong, specialist US consumer bank. Through these five divisions, we are working together for a better financial future for our customers, clients and communities. The Investment Bank helps money managers, financial institutions, governments, supranational organisations and corporate clients manage their funding, investing, financing, and strategic and risk management needs. www.barclays.com/ib.

*Regulatory AUM for private funds are calculated regardless of the nature of the gross assets under management. This includes any uncalled committed capital pursuant to an obligation to make a capital contribution to the fund.

SOURCE HarbourView Equity Partners

 

Download PDF

Categories: News

Tags:

EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

Life Sciences

  • Series A Funding will be used to advance Mosanna’s nasal spray therapy through Phase 2 Clinical Trials
  • Biotech veteran David Weber has been appointed CEO to lead the company through clinical development
  • Obstructive sleep apnea (OSA) affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body’s natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).

“What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue” said Daniela Begolo, Ph.D., Managing Director at EQT Life Sciences, who will be joining the Board of Directors. “MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.” 

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that in OSA patients, the natural airway reflex becomes less active at night, leading to a loss of airway patency and the occurrence of apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting the expansion of Mosanna’s pipeline. 

Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors. 

“Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.” 

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

 

About Mosanna Therapeutics 

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised over $80 million from investors including EQT Life Sciences, Pivotal bioVenture Partners, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. For more information, visit mosanna.com

Categories: News

Tags:

BCI Invests in KKR Tower Platform Pinnacle Towers

KKR

SINGAPORE & VICTORIA, Canada–(BUSINESS WIRE)– KKR, a leading global investment firm, British Columbia Investment Management Corporation (“BCI”), and Pinnacle Towers, an Asia-based digital infrastructure platform with a focus on the Philippines, today announced the signing of definitive agreements under which BCI will acquire a minority stake in Pinnacle Towers from KKR, which will remain the majority shareholder.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608594472/en/

Pinnacle Towers was established in 2020 to serve the rapidly increasing demand for connectivity and quality telecommunications infrastructure in the Philippines. Led by a highly experienced management team, the platform specializes in executing on Build-to-Suit (“BTS”) telecommunications tower projects, optimizing the use and management of Sale-and-Leaseback (“SLB”) assets with leading mobile network operators, and providing ancillary management services to industry players. In the span of five years, Pinnacle Towers has scaled to become the largest independent tower company in the Philippines with around 7,000 towers.1

Lincoln Webb, Executive Vice President & Global Head, Infrastructure & Renewable Resources, BCI, said, “We are excited to work closely with KKR and Pinnacle’s management team to support the growth of the business. The Philippines represents a compelling market for long-term capital, especially in essential digital infrastructure services. This investment aligns with our emerging markets strategy of backing high-quality infrastructure assets alongside strong institutional partners. We look forward to supporting Pinnacle Towers as it continues to enhance digital connectivity and drive meaningful impact across the Philippines.”

Projesh Banerjea, Managing Director, Infrastructure, KKR, said, “We are very proud of the success that we have achieved with Pinnacle Towers to serve the Philippines’ connectivity needs. Since our initial investment, we have collaborated closely with Pinnacle Towers’ outstanding management team to deepen the platform’s capabilities and scale its presence organically and through bolt-on acquisitions. We are delighted to welcome BCI, who share our long-term vision and commitment to developing critical digital infrastructure, as strategic partners and look forward to building on Pinnacle Towers’ strong growth momentum.”

Patrick Tangney, Chairman and CEO of Pinnacle Towers, said, “Over the last five years, with the support of KKR, Pinnacle Towers has grown to become the leading independent tower company in the Philippines. BCI’s investment marks an important milestone in our journey and is a strong endorsement of our mission. With BCI and KKR as strategic partners, we are well-positioned to continue driving greater digital connectivity in the Philippines and across the region.”

BCI Infrastructure & Renewable Resources has a global portfolio with nine active investments in the Asia-Pacific region, including Rakuten Mobile (a leading communications tower company in Japan), Altius (a leading communications tower company in India), and Cube Highways (the largest toll road operator in India). The program continues to expand its presence in the region with the addition of this minority stake acquisition in Pinnacle Towers.

KKR made its investment in Pinnacle Towers from its Asia Infrastructure Funds I and II. KKR first established its global infrastructure team and strategy in 2008 and has since been one of the most active infrastructure investors around the world. KKR’s Asia Pacific infrastructure platform was established in 2019 and has since organically grown to approximately US$13 billion in assets under management.

The transaction is expected to be completed by Q3 2025, subject to customary regulatory approvals.

About BCI

British Columbia Investment Management Corporation (BCI) is amongst the largest institutional investors in Canada, with C$250.4 billion in gross assets under management as of March 31, 2024. Based in Victoria, British Columbia, with offices in Vancouver, New York, and London, U.K., BCI manages a portfolio of diversified public and private market investments on behalf of its British Columbia pension fund and institutional clients. Learn more at www.bci.ca.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Pinnacle Towers

Pinnacle invests in, builds and operates telecommunications infrastructure with a focus on towers and related assets. Pinnacle is an Asia-focused digital infrastructure platform with a strong focus on the rapidly growing Philippines market. Frontier’s leadership team includes founders of a number of highly successful tower companies and former C-level executives from some of the world’s leading wireless operators. KKR first invested in Pinnacle Towers in 2020.

_____________________

1 Including sites contracted to build or acquire

 

Media Contacts

For BCI
Olga Petrycki
+1 778 410 7310
media@bci.ca

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Pinnacle Towers
Hendrik-Jan Kroon
Hendrik@frontiertowersphilippines.com

Source: KKR

 

Download PDF

Categories: News

Tags:

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

No Comments
Thomabravo

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo and Company Management to Accelerate NextGen Healthcare’s Growth

NextGen Healthcare President and COO Srinivas (Sri) Velamoor will Succeed David Sides as CEO after Planned Transition Period; Sides will Continue to Serve on Board of Directors and Remain Material Investor

CHICAGO & SAN FRANCISCO & REMOTE-FIRST COMPANY—NextGen Healthcare, Inc. (“NextGen Healthcare” or the “Company”), a leading provider of innovative, cloud-based healthcare technology solutions, today announced that funds affiliated with Madison Dearborn Partners, LLC (“MDP”), a leading private equity investment firm based in Chicago, have completed their acquisition of a significant ownership position in NextGen Healthcare. Thoma Bravo, a leading software investment firm, retains a significant ownership position in NextGen Healthcare. MDP will partner with Thoma Bravo and Company management to accelerate NextGen Healthcare’s growth.

Since acquiring NextGen Healthcare in a take-private transaction in 2023, Thoma Bravo has helped the Company modernize and enhance its capabilities, solutions, and operating structure to enhance the client experience. As partners, MDP and Thoma Bravo plan to jointly underwrite a material increase in annual R&D investment over the next three years and work with NextGen Healthcare’s leadership team to accelerate the delivery of best-in-class solutions and services to more healthcare clients.

NextGen Healthcare also announced that its Board of Directors has appointed NextGen Healthcare’s President and Chief Operating Officer Srinivas (Sri) Velamoor, as Chief Executive Officer, effective following a planned transition period. Velamoor will succeed David Sides, who will continue to serve on the Board and remain a material investor in NextGen Healthcare. Sides will work closely with Velamoor to ensure a seamless transition and will continue to support the Company’s strategic priorities throughout the transition period and beyond. Velamoor has been instrumental in driving NextGen Healthcare’s growth and innovation agenda in his current role and will assume full responsibility for leading the Company through its continued expansion and development, which is underpinned by the increased investment and ongoing support from MDP and Thoma Bravo.

The choice to elevate an established industry leader and company insider through a thoughtful and seamless transition process reflects the continued commitment of the NextGen Healthcare Board and leadership team to sustaining the Company’s growth and performance momentum and delivering market-leading services to clients.

“It has been an honor to work alongside Sri in leading NextGen Healthcare through its transformation the last several years. I am grateful to our entire NextGen Healthcare team and to our clients for their trust and partnership,” said Sides. “I am excited to support Sri as he takes the reins and leads us into this next phase of accelerating growth and impact for our clients in partnership with MDP and Thoma Bravo.”

“Our investment strategy centers around partnership with management. When we invested in NextGen Healthcare it was apparent to us how integral Sri has been to all aspects of the Company’s success. The succession announcement today is a natural progression from his previous leadership roles with the Company,” said Peter Hernandez, a Senior Vice President at Thoma Bravo. “We are excited for this next chapter with Sri at the helm, and we are pleased that David will continue to play an important role in the success of NextGen Healthcare as a member of the Board.”

“David’s vision and leadership have been instrumental in further cementing NextGen Healthcare as a category leader in the ambulatory Electronic Health Record space,” said Jason Shideler, Partner and Co-Head of Healthcare at MDP. “We are excited to partner with him and Sri to implement a succession plan for the Company and its clients as NextGen Healthcare continuously builds momentum and delivers market leading solutions and a world class service experience.”

“We are excited to welcome the MDP team as strategic partners and look forward to continuing to work with Sri and David in their new roles as they effect a seamless transition and lead this storied healthcare technology franchise into the next chapter of its growth and innovation journey,” said A.J. Rohde, Senior Partner at Thoma Bravo.

“I am humbled and privileged to be entrusted with the leadership of NextGen Healthcare’s incredible global team and to lead us through our next phase of growth and innovation,” said Velamoor. “Our colleagues, clients, and partners are unified behind our vision of achieving Better Healthcare Outcomes for All. And we are incredibly excited to partner with Thoma Bravo and MDP to unlock the many opportunities in front of us to elevate practice performance and reimagine the provider and patient experience.”

Advisors
Goodwin Procter LLP served as legal counsel to NextGen Healthcare. Morgan Stanley & Co. LLC served as lead financial advisor and J.P. Morgan Securities LLC and Evercore also served as financial advisors to NextGen Healthcare. Kirkland & Ellis, LLP served as legal counsel to MDP.

About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology and data solutions. We are reimagining ambulatory healthcare with award-winning Electronic Health Record (EHR), practice management and surround solutions that enable providers to deliver whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a relentless quest to achieve better healthcare outcomes for all. Learn more at nextgen.com, and follow us on Facebook, X, LinkedIn, YouTube, and Instagram.

About Madison Dearborn Partners
Madison Dearborn Partners, LLC (“MDP”) is a leading private equity investment firm based in Chicago. Since MDP’s formation in 1992, the firm has raised aggregate capital of more than $31 billion and has completed over 160 platform investments. MDP invests across four dedicated industry verticals, including healthcare, basic industries, financial services, and technology & government. Drawing on deep industry and operational expertise, MDP works closely with management teams to drive value creation and operational improvement across its portfolio. For more information, please visit www.mdcp.com

About Thoma Bravo
Thoma Bravo is one of the largest software-focused investors in the world with a 40+ year history and approximately $184 billion in assets under management as of March 31, 2025. Through our private equity, growth equity and credit strategies, our firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Our firm has acquired or invested in approximately 535 software and technology companies representing approximately $275 billion of value (including control and non-control investments). Our investment philosophy is centered around working collaboratively with existing management teams to help drive operating results and innovation. Leveraging our deep sector knowledge and strategic and operational expertise, we execute through a partnership-driven approach supported by a set of management principles, operating metrics and business processes. We support our companies by investing in growth initiatives and strategic acquisitions designed to drive long-term value.

Read the release on Business Wire here.

Categories: News

Tags:

Our Investment in Cursor – accel

Accel

We’re pleased to announce our investment in Cursor, the company shaping the future of software engineering. What Michael, Aman, Arvid, and Sualeh have accomplished in just a few short years is without precedent, and it’s clear they’re only getting started.

As software has accelerated every company and industry over the past several decades, tools supporting engineering teams have flourished – yet astonishingly, the process of writing code itself has hardly changed. Cursor shrinks the gap between human intent and action.  We believe it will become the collaborative interface between humans and computers, where every keystroke, action or inaction is an exchange of information that helps to accelerate cycles and achieve better outcomes. With relentless execution and distinctive product taste, the Cursor team is making software engineering a seamless extension of the human brain.

With over $1.5 billion invested in AI-native companies, we have observed the compounding leadership effect of winners in certain categories. In coding, developer choice —> wider distribution & deeper engagement —> higher fidelity keystroke data —> compounding product differentiation. With market leadership comes disproportionate access to talent, capital, GPU capacity, and marketplace influence.

The future is uncertain, but it will likely involve various configurations of humans and agents writing code together.  Today, Cursor changes the paradigm for building software; tomorrow, we believe it will be the operating system for human-machine collaboration across all developers.  We’re delighted to back Michael and this incredibly talented team for the ambitious journey ahead.

Categories: News

Tags:

Coller Capital expands global reach through strategic partnership with Allfunds

Coller Capital

  • The partnership will distribute CollerEquity and CollerCredit to accredited private investors, wealth managers and family offices.
  • It will provide global individual investors with access to institutional-quality private equity and credit secondaries, enabling them to benefit from the liquidity and resilience that private markets secondaries afford.

London 6th June 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, has today announced a global distribution partnership with Allfunds, the leading end-to-end WealthTech partner for the wealth and asset management industries with more than $1.5 trillion assets under administration across Mutual Funds, Alternative Assets and ETFs. This global partnership will see Coller Private Equity Secondaries (CollerEquity) and Coller Private Credit Secondaries (CollerCredit) made available to the 19,000 accredited private investors, wealth managers and family offices on the Allfunds platform.

CollerEquity launched in July 2024. The Fund’s portfolio consists of institutional quality private equity assets diversified by GP-manager, and fund vintage as well as by geography and sector. Alongside diversification, the Fund seeks to deliver a combination of absolute and risk-adjusted returns and the opportunity for more liquidity than traditional private equity funds.

CollerCredit launched in October 2024. The portfolio is diversified across vintages, managers, industrial sectors and geography. While its core focus is on senior direct lending opportunities, it has the flexibility to invest across other credit strategies opportunistically if risk-adjusted returns and liquidity profiles are deemed to be appropriate.

Both CollerEquity and CollerCredit and its regional feeder funds are available to professional and qualified investors in a range of global jurisdictions, including across Europe, the Middle East, Canada, Asia, and Australia in compliance with local law. The Funds’ clients are supported by Coller’s Private Wealth Secondaries Solutions (PWSS) team, which now consists of 50 dedicated professionals supported by the wider Coller platform. Both Funds provide investors with access to Coller Capital’s 35 years of secondaries investment expertise and its global platform. They offer monthly subscriptions and quarterly redemptions, and can be accessed with USD 50,000 minimum commitment.

Jake Elmhirst, Partner, Head of Private Wealth Secondaries Solutions and Deputy Head of Capital Formation at Coller Capital, said: “Coller Capital has a long-standing reputation for innovation in private markets secondaries, and that spirit drives our wealth strategy. The strategic investment approach underpinning CollerEquity and CollerCredit provides investors with diversified, risk-adjusted returns, as well as portfolio resilience in times of wider market dislocation. This partnership with Allfunds widens the spectrum of investors who have access to these benefits, and we look forward to working with their team.”

Boris Maeder, Managing Director and Head of International Private Wealth Distribution at Coller Capital, said: “Through this global partnership with Allfunds, we are making CollerEquity and CollerCredit more accessible to a wider range of investors. It represents a meaningful step in broadening access to private equity and private credit secondaries, which are powerful tools for portfolio diversification, liquidity and resilience – including in times of wider market uncertainty.”

Borja Largo, Chief Fund Groups Officer for Allfunds said: “This partnership with Coller Capital unlocks exciting new access to private market secondaries for our clients, strengthening Allfunds’ position as the largest and most comprehensive marketplace for wealth and asset management solutions. We remain dedicated to continuously enhancing our private markets offering to empower our clients and help them grow.”

Coller Capital has offices in London, New York, Hong Kong, Beijing, Seoul, Luxembourg, Zurich, Melbourne, Montreal and Singapore. The firm manages $40 billion in secondaries across private equity, private credit, and other private market vehicles and has 35 years of experience in the secondary private capital market.

About Coller Private Equity Secondaries – (“CollerEquity”) and Coller Private Credit Secondaries (“CollerCredit”)

THIS IS A MARKETING COMMUNICATION IN RESPECT OF THE FUND. PLEASE REFER TO THE PROSPECTUS, KEY INFORMATION DOCUMENT, GOVERNING AND OTHER RELEVANT DOCUMENTS FOR THE FUND BEFORE MAKING ANY INVESTMENT DECISION

Potential investors should be aware that an investment in the CollerEquity and/or CollerCredit (including any related overflow, co-investment, or other vehicles, the “Funds”) is speculative and involves a high degree of risk, and is suitable only for those investors who have the financial sophistication and expertise to evaluate the merits and risks of an investment in the Fund(s) and for which such Fund(s) do(es) not represent a complete investment program. An investment should only be considered by persons who can afford a loss of their entire investment. The following is a summary of only certain considerations and is qualified in its entirety by the more detailed risks and conflicts in the CollerEquity and CollerCredit prospectuses. Investors are urged to consult with their own tax and legal advisors about the implications of investing in the Fund. Fees and expenses can be expected to reduce the overall return of the Fund.

Investors should carefully consider the investment objectives, risks, charges and expenses of CollerEquity and/or CollerCredit. This and other important information about the Funds are contained in the relevant prospectus. Please read the prospectus(es) carefully before investing. The CollerEquity Prospectus can be found here. The CollerCredit Prospectus can be found here.

General Risks. Coller Capital cannot ensure that it can choose, make and realize investments in any particular investment fund or portfolio of investment funds. There is no assurance CollerEquity and/or CollerCredit will be able to generate returns for the investors or that returns will be commensurate with the risks of investing in the type of companies and investments in which CollerEquity and/or CollerCredit may indirectly invest. An investment in CollerEquity and/or CollerCredit should only be considered by persons who can afford a loss of their entire investment. There can be no assurance that CollerEquity and/or CollerCredit’s investment objectives will be achieved or that investors will receive a return on their capital. Any investment in CollerEquity and/or CollerCredit entails risks, including but not limited to the risk of losing all or part of the amount invested. There can be no assurance that CollerEquity and/or CollerCredit will be able to implement its investment strategy or achieve its investment objectives.

Specific risks: Lack of Operating History. Diversification. Competition. Limited Current Return. Illiquidity; Transfer Restrictions. Leverage. Exchange Rate Fluctuations.

Performance is generally subject to taxation which depends on the particular situation of each investor and which may change in the future. The operating or chosen currency of an investor may also impact upon returns that may be realised by that investor.

Capital is at risk and investors may not receive back the amount they invest. The strategy of the Funds does not guarantee a profit or ensure protection against losses. There can be no assurance that the Funds will achieve their objectives or avoid significant losses.

Mentions
Black and white formal headshot of Jake Elmhirst.
Jake Elmhirst

Partner, Head of Private Wealth Secondaries Solutions and Deputy Head of Capital Formation
Black and white formal headshot of Boris Maeder.
Boris Maeder

Managing Director and Head of International Private Wealth Distribution
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

News
6 Ju

Categories: News

Tags: